BioLife Solutions, Inc., a developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, has entered into a ten year supply agreement with Bellicum Pharmaceuticals, a developer of cellular immunotherapies for cancers and orphan inherited blood disorders.
BioLife's CryoStor clinical grade cell freeze media is incorporated into Bellicum's manufacturing process for several cellular immunotherapies targeting blood cancers and solid tumors.
Mike Rice, BioLife President & CEO, commented, "We are pleased to support Bellicum with this long term supply agreement, which underscores the value and utility of our biopreservation media products in the high growth cell therapy industry. The last half of 2016 and 2017 will be very exciting and encouraging for cancer patients, our customers, and BioLife shareholders. Several customers' cellular immunotherapies continue to progress through late stage clinical trials and the BLA submission and regulatory approval process. As these customers obtain regulatory approvals and commence commercial scale manufacturing, we expect significantly increased demand for CryoStor and HypoThermosol®, our best in class biopreservation media products."
BioLife management estimates that CryoStor and HypoThermosol, BioLife's cell and tissue storage and shipping media, are incorporated into more than 220 pre-clinical validation projects and clinical trials of cell-based therapies targeting blood cancers, solid tumors, vision loss, heart disease, stroke, and movement disorders such as osteoarthritis.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.